Humana (HUM) Q4 FY25 earnings call: guidance and Q&A

How does enterprise-accretive growth translate to earnings outside MA underwriting, and how do the slightly below breakeven MA margins compare for retained vs. new growth?

Celeste explained that CenterWell (Pharmacy, PCO, home health) provides significant tailwinds for enterprise accretion. Individual MA margins are slightly below breakeven for 2026. New and continuing members have similar overall margins due to different factors: continuing members are disproportionately impacted by Stars headwind, while new members face acquisition costs and potentially higher MLR. George added that MRA improvement, medical management, and increased paneling to value-based partners drive margin improvement over time.

“So net-net, the overall margins for the existing and the new cohorts are fairly consistent, but for very different reasons.”

asked by Stephen Baxter · answered by Celeste Mellet

What is the typical margin progression for new member cohorts over 3-5 years, and what is the net benefit from returning to Top Quartile Stars by 2027?

Celeste detailed that margin progression sees a substantial pickup in year two due to a lower marketing load and MLR improvement, with continued gradual improvement thereafter. Jim clarified that the Stars target is the 75th percentile, not a specific number, to account for industry policy changes and provide planning flexibility, emphasizing that the 2028 targets already reflect this 75th percentile assumption.

“The challenge that we have in giving you a specific number is that this does, at the end of the day, tie back to where is the industry performing and what are the policy changes impacting Stars.”

asked by Justin Lake · answered by James Rechtin

How did 2026 expectations change from Investor Day, and what parts of the current guidance are most conservative?

Celeste stated the biggest difference is the embedded conservatism in the numbers, including a broader 'haircut' given known headwinds and tailwinds. While some assumptions like MRA have inherent conservatism, the overall guide reflects a more cautious approach. Cost trends embedded are similar to 2025 (higher end of mid-single-digit medical, low double-digit Rx), but slightly higher for 2026 due to the inclusion of Doc Fix.

“I think the biggest difference between where we were at Investor Day and where our guidance played out is really the embedded conservatism in our numbers.”

asked by Ann Hynes · answered by Celeste Mellet

Has the view on the ultimate margin profile for the larger book changed for 2028, specifically regarding Top Quartile Stars and the 2027 rate notice?

Celeste highlighted that the current growth provides a significant jump towards the 2028 target, with substantial operating cost ratio improvement. Jim reiterated confidence in Stars mitigation through operational improvements and targeted interventions, acknowledging inherent risk. On the rate notice, he stated the company will adjust to the final rates and advocate for members, emphasizing that the focus is on achieving a long-term sustainable margin trajectory.

“We are focused on getting to the right long-term sustainable, durable, attractive margin. And yes, we're going to retain as many members as we can along the way.”

asked by Joshua Raskin · answered by James Rechtin

What is the visibility for 2027 bid adjustments, and how will Humana balance margin trajectory with membership growth given the LTV commentary?

Jim confirmed good visibility into member performance by April/May, allowing for timely bid adjustments for 2027. He clarified that the primary focus is on achieving the right long-term sustainable and attractive margin trajectory, with member retention being a goal, but new member growth is not the central focus. The company will adapt to the funding environment to ensure margin progression.

“Our focus is on retaining membership to be sure, but it is on getting -- the first goal is to get to the margin trajectory that this business needs to be on over the long term, right?”

asked by Kevin Fischbeck · answered by James Rechtin

Does Humana have outsized exposure to specific components of the rate notice, and what is the status of statutory capital efficiency efforts?

Jim stated that the policy changes in the rate notice (v28) are expected to impact most of the industry within a narrow band, suggesting no outsized exposure for Humana. Celeste explained that most of the capital efficiency work, particularly redomestication (legal entity restructuring), has been completed, but further opportunities exist in areas like reinsurance for future periods.

“The changes that have occurred from a policy standpoint this year do not have the same type of variance that v28 had. In general, most of the industry should be impacted around a pretty narrow band around the industry mean.”

asked by Erin Wright · answered by James Rechtin

What proportion of MA members are in capitated vs. other risk models, and how has this changed for 2026?

George stated that the proportion of MA members in different risk models remains relatively stable: about one-third in full risk, one-third in other value-based models, and one-third in non-value-based or basic pay-for-performance. He noted that an influx of new members typically causes a temporary dip in paneling to value-based partners at the start of the year, which then builds up as members choose PCPs or through claims-based attribution.

“The percent of membership is relatively the same, about 1/3 in full risk, 1/3 in value-based, other types of value-based and then 1/3 that are in either non-value-based or just some basic pay-for-performance.”

asked by Matthew Gillmor · answered by George Renaudin